ARTICLE
16 November 2022

China Approves World's First Denosumab Biosimilar

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
Luye Pharma Group announced last week that China's National Medical Products Administration has approved a marketing launch of BOYOBEI® for treatment of postmenopausal women with osteoporosis at high risk of fractures.
China Food, Drugs, Healthcare, Life Sciences

Luye Pharma Group announced last week that China's National Medical Products Administration has approved a marketing launch of BOYOBEI® for treatment of postmenopausal women with osteoporosis at high risk of fractures. Luye Pharma Group, in conjunction with its subsidiary Boan Biotech, is now the first company in the world to receive approval for a PROLIA®/XGEVA® (denosumab) biosimilar product. Denosumab is a fully-human IgG2 monoclonal antibody that binds to RANKL and is used to treat osteoporosis including by reducing resorptive bone loss, increasing bone strength, and reducing fractures. According to the press release, BOYOBEI® is also being developed for markets outside of China, including Europe and the United States, and will eventually seek marketing approval globally.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More